Literature DB >> 22135086

High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.

S Guddat1, E Solymos, A Orlovius, A Thomas, G Sigmund, H Geyer, M Thevis, W Schänzer.   

Abstract

A new multi-target approach based on liquid chromatography--electrospray ionization tandem mass spectrometry (LC-(ESI)-MS/MS) is presented to screen for various classes of prohibited substances using direct injection of urine specimens. With a highly sensitive new generation hybrid mass spectrometer classic groups of drugs--for example, diuretics, beta2-agonists--stimulants and narcotics are detectable at concentration levels far below the required limits. Additionally, more challenging and various new target compounds could be implemented. Model compounds of stimulant conjugates were studied to investigate a possible screening without complex sample preparation. As a main achievement, the integration of the plasma volume expanders dextran and hydroxyethyl starch (HES), commonly analyzed in time-consuming, stand-alone procedures, is accomplished. To screen for relatively new prohibited compounds, a common metabolite of the selective androgen receptor modulator (SARMs) andarine, a metabolite of growth hormone releasing peptide (GHRP-2), and 5-amino-4-imidazolecarboxyamide ribonucleoside (AICAR) are analyzed. Following a completely new approach, conjugates of di(2-ethylhexyl) phthalate (DEHP) metabolites are monitored to detect abnormally high levels of plasticizers indicating for illicit blood transfusion. The assay was fully validated for qualitative purposes considering the parameters specificity, intra- (3.2-16.6%) and inter-day precision (0.4-19.9%) at low, medium and high concentration, robustness, limit of detection (1-70 ng/ml, dextran: 30 µg/ml, HES: 10 µg/ml) and ion suppression/enhancement effects. The analyses of post-administration and routine doping control samples demonstrates the applicability of the method for sports drug testing. This straightforward and reliable approach accomplishes the combination of different screening procedures resulting in a high-throughput method that increases the efficiency of the labs daily work.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22135086     DOI: 10.1002/dta.372

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  5 in total

1.  Comprehensive automation of the solid phase extraction gas chromatographic mass spectrometric analysis (SPE-GC/MS) of opioids, cocaine, and metabolites from serum and other matrices.

Authors:  Oliver Lerch; Oliver Temme; Thomas Daldrup
Journal:  Anal Bioanal Chem       Date:  2014-05-02       Impact factor: 4.142

2.  Mildronate (Meldonium) in professional sports - monitoring doping control urine samples using hydrophilic interaction liquid chromatography - high resolution/high accuracy mass spectrometry.

Authors:  Christian Görgens; Sven Guddat; Josef Dib; Hans Geyer; Wilhelm Schänzer; Mario Thevis
Journal:  Drug Test Anal       Date:  2015-04-05       Impact factor: 3.345

3.  Identification of metabolomic changes in horse plasma after racing by liquid chromatography-high resolution mass spectrometry as a strategy for doping testing.

Authors:  Toshiki Ueda; Teruaki Tozaki; Satoshi Nozawa; Kenji Kinoshita; Hitoshi Gawahara
Journal:  J Equine Sci       Date:  2019-10-02

4.  Artificial intelligence-based models for the qualitative and quantitative prediction of a phytochemical compound using HPLC method.

Authors:  Abdullahi Garba Usman; Selin IŞik; Sani Isah Abba; Filiz MerİÇlİ
Journal:  Turk J Chem       Date:  2020-10-26       Impact factor: 1.239

5.  Investigation of urinary excretion of hydroxyethyl starch and dextran by uhplc-hrms in different acquisition modes.

Authors:  S Esposito; K Deventer; A J Giron; K Roels; L Herregods; A Verstraete; P Van Eenoo
Journal:  Biol Sport       Date:  2014-04-05       Impact factor: 2.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.